完全由治疗性核酸相似物构成的aptamers用于向癌症治疗
Journal of the American Chemical Society
|January 24, 2022
概括
研究人员研制出一种类似DNA的分子, 完全由癌症药物制成, 这种新的方法显著改善了药物负载,并加强了向癌症治疗.
科学领域:
- 生物化学
- 分子生物学
- 癌症学
背景情况:
- 由于aptamers的特定结合,aptamer-药物结合物 (ApDCs) 在向癌症治疗中表现有前途.
- 传统的ApDC具有药物载荷能力的局限性,因为aptamers主要作为药物结合有限的向部分.
研究的目的:
- 开发一种新型药物输送系统, 增强药物载荷和向癌细胞杀伤能力.
- 通过用临床批准的核酸相似物代替天然核酸相似物来制造类似DNA的寡聚物,称为药.
主要方法:
- 用于合成整个药物构成的DNA类寡合物 (药).
- 评估了药对癌细胞表面受体的向能力和结合性.
- 在诱导癌细胞亡和抑制瘤进展方面评估了药剂的有效性.
主要成果:
- 药物体保留了原始体的向能力,特别是与癌细胞上过度表达的受体结合.
- 这种新型药剂达到了100%的药物加载比率.
- 通过酶介导的药物释放,药物诱导癌细胞亡并抑制瘤的进展.
结论:
- 通过提供高药载荷和固有的治疗活性,药对传统的ApDC来说是一个显著的进步.
- 这种药物输送策略有可能通过将向和强效药物输送结合在单个分子中来改善向癌症治疗.
相关概念视频
Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
siRNA - Small Interfering RNAs
17.2K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.2K
Targets for Drug Action: Overview
7.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


